ReviewCancers2021

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.

Koichi Ando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.